



INVESTORS.com

MEDIA CENTER



Timely videos from market experts **Click Here**

SUBSCRIBE/RENEW

[Forex Trading at Forex.com](#)

[Shell MasterCard: 5% rebates on all pur](#)

[HOME](#)

[NEWS & ANALYSIS](#)

[IBD STOCK LISTS](#)

[HOW TO INVEST](#)

NEWS & ANALYSIS

Today in IBD®
Daily Stock
Analysis **NEW!**

IBD® Indexes
Option Center
Media Center
ETF Center
Tech Center

IBD®extra! Newsletter
Investing Tools

IBD STOCK LISTS

The IBD® 100
Screen Of The Day
Stocks On The Move
CAN SLIM® Select

HOW TO INVEST

Financial Dictionary
Investor's Corner
Learning Center
What Is CAN SLIM®
IBD® Workshops
IBD® Community

[Search the Ask IBD®
Knowledgebase](#)

Ask IBD®

FREE MEMBERSHIP

SERVICES

IBD® Store

News | Headlines


IBD® Tables **Try it FREE!**
NEW! EXPANDED INTERACTIVE TABLES

First Patient Dosed with KX2-391 in Phase 1 Clinical Trial

BUFFALO, N.Y., Nov 27, 2007 /PRNewswire via COMTEX/ -- Kinex Pharmaceuticals LLC, announced today that their drug KX2-391 (KX01) has begun Phase 1 human testing. The study is entitled "A combined rising single-dose (RSD) and rising multiple-dose (RMD) Phase 1 study to evaluate safety, tolerability and pharmacokinetics of KX2-391 in patients with advanced malignancies that are refractory to conventional therapies". The drug belongs to an emerging new family of targeted cancer treatments called protein kinase inhibitors.

Dosing has begun at Roswell Park Cancer Institute in Buffalo, N.Y., and will commence in the next several days at M.D. Anderson Cancer Center in Houston, Texas. The trial is expected to enroll 50 patients with advanced solid tumors and lymphoma and will evaluate safety, tolerability and pharmacokinetics. Exploratory biomarker studies will also be involved.

"What's remarkable about this compound is that, in preclinical testing, it has worked against every cancer and in every animal model," said David Hangauer, a University at Buffalo chemistry professor whose work was integral to the drug's creation. Hangauer is a co-founder of Kinex and serves as the Company's Senior



Affiliate Program

CAN SLIM® Licensing Opportunities

IBD® Calendar **NEW!**

RSS Feeds

Investors.com Mobile

Rates & Calculators

IBD® Retail

Locations


IBD Careers **NEW!**

Contact IBD®

Corporate News

About IBD®/

Press Info



Try it FREE!



Continue

ADVERTISING

[IBD® Partners](#)

[Classified](#)

[Reprints](#)

[Media Kits](#)

[Editorial Calendar](#)

[Make investors.com your homepage](#)

Vice President of Research and Development. KX2-391 targets an important cell signaler called Src kinase, a protein linked to the rapid growth and spread of cancer cells. A potential advantage of Kinex's kinase inhibitor is that it disrupts Src at a site different from where other currently studied compounds are targeted, reducing the chance that patients will develop resistance to the new drug, Hangauer said.

"As we go further in the drug's development, and do broader testing, we get better and better data," said Allen Barnett, Chief Executive Officer of Kinex Pharmaceuticals. "We are extremely enthusiastic about the potential for KX2-391 because it represents a unique approach for the treatment of cancer. It is a first-in-class drug that has the potential to provide patients with a safe and effective treatment for a broad range of tumor types," said Barnett.

Contact: Lyn Dyster

Kinex Pharmaceuticals,
(716) 881-8984

SOURCE Kinex Pharmaceuticals LLC

<http://www.kinexpharma.com/>

Copyright (C) 2007 PR Newswire. All rights reserved

Copyright ©2007 MarketWatch, Inc. All rights reserved. Please see our [Terms of Use](#). MarketWatch, the MarketWatch logo, and BigCharts are registered trademarks of MarketWatch, Inc."

[Return to top of page](#)

Updated! — Global Markets Will Weather Worries *By Fisher Investments*

Despite the hullabaloo, the third quarter ended with a positive return for both US and global stocks. Equity investments were again the right choice, highlighting why we believe trying to time short-term volatility isn't a good idea... [Full Story](#)

SPONSORED LINKS

Free SAP CFO Report
A Full Suite Of Business Solutions Designed For The Office Of The CFO From SAP.
Free White Paper
SAP.com

Exchange Traded Funds
iShares Funds - Brought to you by Barclays Global Investors
www.iShares.com

Buy High-Yield Bonds
Our Bonds Cost Less. Period. Wholesale Prices, \$10.95/Trade.
www.zionsbank.com

Options Education Software
Comprehensive options education software at your fingertips. Free for 30 days. Sign up now!
www.OIOnline.com

Stock Option Trading Resources
\$4.95 Trades + \$.65 per Contract, Market or Limit, No Minimums - Rated "Best In Costs" By Barron's
www.TradeKing.com

[Home](#) [Site Map](#) [IBD Learning Center](#) [Today In IBD](#) [IBD Subscriber Tools](#) [Advertising Info](#) [Partner Programs](#) [Affiliate Program](#)
[Contact Us](#) [RSS Feeds](#) [IBD Careers](#)

Investor's Business Daily, IBD and CAN SLIM and their corresponding logos are registered trademarks of Data Analysis Inc.
[Copyright and Trademark Notice](#)

© 2000-2007 Investor's Business Daily, Inc. All rights reserved.
[Privacy Statement](#) [Terms and Conditions of Use](#)

More sites from IBD: IBDeditorials.com

 **William O'Neil + Co.** © 2007 [William O'Neil + Co. Incorporated](#). All Rights Reserved. The William O'Neil + Co. Database contained herein are provided by William O'Neil + Co. Incorporated and are used by IBD under license. Daily Graphs and Daily Graphs Online are trademarks of William O'Neil + Co. Incorporated or its subsidiaries.



This site is powered by HyperFeed® market data. Price and Volume data is delayed 20 minutes unless otherwise believed accurate but is not warranted or guaranteed by HyperFeed Technologies, Inc. and is subject to HyperFeed Technologies, Inc. terms. All times are Eastern United States.

*Index pricing and Stocks On The Move data may be delayed more than 20 minutes due to the auto-refresh schedule for these features